Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Equity Income (2020 - 2023)

Historic Equity Income for BeOne Medicines (BEIGF) over the last 4 years, with Q4 2023 value amounting to -$3.9 million.

  • BeOne Medicines' Equity Income rose 2928.53% to -$3.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$16.2 million, marking a year-over-year increase of 2625.48%. This contributed to the annual value of -$16.2 million for FY2023, which is 2625.48% up from last year.
  • Per BeOne Medicines' latest filing, its Equity Income stood at -$3.9 million for Q4 2023, which was up 2928.53% from -$10.1 million recorded in Q3 2023.
  • BeOne Medicines' 5-year Equity Income high stood at $23.2 million for Q3 2021, and its period low was -$17.0 million during Q1 2022.
  • Moreover, its 4-year median value for Equity Income was -$2.4 million (2021), whereas its average is -$1.4 million.
  • Over the last 5 years, BeOne Medicines' Equity Income had its largest YoY gain of 231364.5% in 2021, and its largest YoY loss of 1166521.74% in 2021.
  • BeOne Medicines' Equity Income (Quarter) stood at $1.9 million in 2020, then plummeted by 614.79% to -$9.5 million in 2021, then surged by 41.44% to -$5.6 million in 2022, then rose by 29.29% to -$3.9 million in 2023.
  • Its Equity Income stands at -$3.9 million for Q4 2023, versus -$10.1 million for Q3 2023 and -$2.0 million for Q2 2023.